Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches
Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. Image credit: Shutterstock.com/Billion Photos
Regina Fritsche Danielson Aptamer Groupmar Arron Tolley Head Of Research Early Development Aptamer Group
Source: news-medical.net